Interstitial Lung Disease Spotlight-Interstitial Lung Disease after COVID-19 - Insights into Incidence, Prognosis, and Management

Interstitial Lung Disease after COVID-19 - Insights into Incidence, Prognosis, and Management

Video Transcription

Video Summary

Corey Kershaw, a medical professional from UT Southwestern Medical Center, discusses interstitial lung disease (ILD) after surviving COVID-19. Kershaw covers the incidence and risk factors of ILD after COVID-19, focusing on patients who have moderate to severe disease. He presents a case study of a patient who was hospitalized with moderate disease, needed oxygen, and was discharged on three liters of oxygen. The patient had a history of hypertension but was overall healthy, with normal lung function tests. A CT scan showed abnormal findings, including ground glass opacities and irregular lines, which are characteristic of ILD. Kershaw analyzes various studies on post-COVID-19 ILD and finds that most patients improve over time, with a decrease in abnormalities on CT scans. The likelihood of persistent abnormalities increases with the severity of the initial COVID-19 disease. Older patients, those with hypertension, and those with higher levels of inflammation markers are at a higher risk for persistent ILD. While some patients may require treatment, Kershaw emphasizes the importance of close monitoring and follow-up for these patients. He also highlights the role of vaccinations to prevent COVID-19 and subsequent ILD. Overall, Kershaw's presentation provides insights into the incidence, risk factors, and management of ILD after surviving COVID-19.

Meta Tag

Category Diffuse Lung Disease

Speaker Corey Kershaw, MD, FCCP

Speaker Anna Podolanczuk, MD

Speaker Harpreet Grewal, MD

Keywords

interstitial lung disease

COVID-19

CT scan

abnormal findings

persistent ILD

risk factors

management

vaccinations